Nurosym has announced a wearable vagus nerve stimulation device for people interested in non-invasive nervous system support and heart rate variability (HRV). The CE-marked Class IIa medical device uses targeted auricular stimulation designed for repeatable vagal pathway engagement.
More information is available at https://nurosym.com/
The news comes as heart rate variability receives growing attention in conversations around stress and recovery. HRV reflects the variation in time between consecutive heartbeats and can change in response to different physical and everyday demands.
Nurosym uses Parasym's proprietary Auricular Vagal Neuromodulation Technology (AVNT™) to deliver controlled auricular stimulation through the ear. The device clips onto the tragus, where the vagus nerve reaches the skin of the ear. Controlled electrical impulses are designed to engage vagal afferent pathways communicating between the body and brain.
The device is designed around consistent and repeatable pathway engagement over time. Most people use Nurosym for around 30 minutes, once or twice a day, while working, reading or watching television. Its wearable design is intended to support simple integration into an everyday routine.
Heart rate variability is among the measures investigated in clinical research using Nurosym's technology. In clinical studies, heart rate variability increased by an average of 18%.*
The device is supported by more than 10 years of research and development and 60+ completed clinical studies. There are also 100+ ongoing clinical studies underway and 150+ research partners. Nurosym has been used across more than 5 million user sessions.
Nurosym is designed to support the nervous system alongside existing care, not instead of it. Anyone experiencing symptoms or concerned about a medical condition should speak with a healthcare professional.
More information about Nurosym and its clinically tested vagus nerve stimulation technology is available at https://nurosym.com/
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.